Elevated miR-34a induced by lipotoxicity and inflammation mediates pathophysiological communication between hepatocytes and hepatic stellate cells in liver fibrosis
Increased mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) imposes an urgent need to elucidate the pathogenesis of MASLD so that novel therapeutic strategies may be identified. Here, we delineate the mechanism of microRNA-34a-5p (miR-34a) in the progressive liver injury of MASLD and liver fibrosis. Specifically, liver tissue from patients with obesity-associated hepatic steatosis, metabolic dysfunction-associated steatohepatitis (MASH), and fibrosis, as well as liver tissues from a human MASLD-like mouse model, were utilized for this study. We found that lipotoxicity resulting from obesity or saturated free fatty acid treatment induced miR-34a expression in human liver tissue or mouse hepatocytes, which was accompanied by dysregulation of lipoprotein metabolism, activation of inflammation, and ballooning degeneration of hepatocytes. Moreover, increased cellular miR-34a induced by treatment with saturated fat, palmitic acid, or transfection of miR-34a mimic was released from injured hepatocytes into the conditional cell culture media, which mediated pathological communications between hepatocytes and hepatic stellate cells, activated pro-fibrogenic signaling in hepatic stellate cells, and induced extracellular matrix remodeling. These phenotypes were recapitulated in a human MASLD-like mouse model in which MASLD and liver fibrosis were induced via streptozotocin treatment and high-fat feeding. Elevated expression of miR-34a was found in mouse liver tissues, which conveyed the progressive liver injury from steatosis to MASH and liver fibrosis. Our findings demonstrate that elevated miR-34a induced by lipotoxicity and metabolic inflammation are key driving factors in the progressive liver injury from simple steatosis to MASH and liver fibrosis.
Authors
- Qihua Duan
- Bingrui Zhang
- Szczepan Kaluzny
- Edward N. Harris (ORCID: https://orcid.org/0000-0001-7045-1040)
- Qiaozhu Su (ORCID: https://orcid.org/0000-0001-8434-1408)
- Cunchuan Wang (ORCID: https://orcid.org/0000-0003-2576-7462)
- Rongxue Wu (ORCID: https://orcid.org/0000-0003-4857-4655)
- Guangnan Liu (ORCID: https://orcid.org/0009-0005-2054-3314)
- Yan Chen (ORCID: https://orcid.org/0000-0003-0371-5776)
- Ruixiang Hu (ORCID: https://orcid.org/0009-0004-2068-8583)
- Henry Wade
Institutions
- University of Nebraska–Lincoln (US)
- Queen's University Belfast (GB)
- Guangxi Medical University (CN)
- University of Chicago (US)
- First Affiliated Hospital of Jinan University (CN)
Publication Details
- Journal
- Genes & Diseases
- Published
- 2025-04-18
- DOI
- https://doi.org/10.1016/j.gendis.2025.101648
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Department for the Economy
- British Heart Foundation
- Queen's University Belfast
- Queen's University
- National Institutes of Health